Washington, DC - The U.S. Food and Drug Administration will hold a joint meeting of the Pediatric Advisory Committee and Drug Safety and Risk Management Advisory Committee on September 26 and 27.

Dallas, Texas - People suffering from insomnia may have an increased risk of coronary artery disease, heart failure and stroke, according to new research in the American Heart Association’s journal Circulation.

Washington, DC - Aided by a high-powered brain scanner and a 3D printer, NIH researchers peered inside the brains of hundreds of multiple sclerosis patients and found that dark rimmed spots representing ongoing, “smoldering” inflammation, called chronic active lesions, may be a hallmark of more aggressive and disabling forms of the disease.

Washington, DC - Though food allergy affects more than 4.8 million children in the United States, no approved preventative treatments currently exist. While experimental desensitization strategies are available in research settings, people with food allergies must avoid known allergens and are advised to carry injectable epinephrine to prevent potentially life-threatening allergic reactions caused by  accidental exposures. To help alleviate this risk, a new study to evaluate an experimental treatment for food allergy launched today. The study is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health; Genentech, a member of the Roche Group; and Novartis Pharmaceuticals Corporation.

Dallas, Texas - Non-invasive techniques and devices for assessing blood flow and other diagnostic considerations for people with critical limb ischemia are addressed in a new scientific statement from the American Heart Association, published in the Association’s flagship journal Circulation.

Washington, DC - Researchers have found that anti-inflammatory biologic therapies used to treat moderate to severe psoriasis can significantly reduce coronary inflammation in patients with the chronic skin condition. Scientists said the findings are particularly notable because of the use of a novel imaging biomarker, the perivascular fat attenuation index (FAI), that was able to measure the effect of the therapy in reducing the inflammation.